Efficacy and safety of tislelizumab plus cetuximab and irinotecan in patients with previously treated RAS wild-type advanced colorectal cancer: Preliminary findings of a phase II, single-arm study.

被引：0
|
作者：
Xu, Xiaojing
Yu, Yiyi
Wang, Yan
Cui, Yuehong
Li, Wei
Liang, Li
Li, Qian
Yu, Shan
Feng, Yi
Liu, Qing
Zhang, Pengfei
Lv, Minzhi
Liu, Tianshu
机构：
[1] Fudan Univ, Dept Oncol, Canc Ctr, Zhongshan Hosp, Shanghai, Peoples R China
[2] Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Canc Ctr, Shanghai, Peoples R China
[3] Fudan Univ, Zhongshan Hosp, Dept Biostat, Canc Ctr, Shanghai, Peoples R China
[4] Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3566
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase II study of avelumab in combination with cetuximab in pre-treated RAS wild-type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon.
    Troiani, Teresa
    Martinelli, Erika
    Ciardiello, Davide
    Zanaletti, Nicoletta
    Cardone, Claudia
    Borrelli, Carola
    Avallone, Antonio
    Falcone, Alfredo
    Maiello, Evaristo
    Bordonaro, Roberto
    Santini, Daniele
    Garufi, Carlo
    De Braud, Filippo G.
    Pinto, Carmine
    Gridelli, Cesare
    Ciardiello, Fortunato
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [42] Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer
    Van Cutsem, Eric
    Yaeger, Rona
    Delord, Jean-Pierre
    Tabernero, Josep
    Siu, Lillian L.
    Ducreux, Michel
    Siena, Salvatore
    Elez, Elena
    Kasper, Stefan
    Zander, Thomas
    Steeghs, Neeltje
    Murphy, Danielle
    Edwards, Michelle
    Wainberg, Zev A.
    ONCOLOGIST, 2023, : e1209 - e1218
  • [43] Initial Report of Phase II Study on Bi-weekly SOX plus Cetuximab Treatment for Wild-type K-RAS Advanced and Recurrent Colorectal Cancer
    Ogawa, Masaichi
    Anan, Tadashi
    Suzuki, Toshiaki
    Okuma, Masahisa
    Ichihara, Kohei
    Hasegawa, Takuo
    Yoshida, Kazuhiko
    Yanaga, Katsuhiko
    ANTICANCER RESEARCH, 2016, 36 (05) : 2505 - 2511
  • [44] A PHASE II STUDY OF CETUXIMAB PLUS IRINOTECAN/S-1 AS FIRST-LINE TREATMENT IN KRAS WILD-TYPE METASTATIC COLORECTAL CANCER
    Masuishi, T.
    Sakai, Y.
    Matsui, T.
    Nakamura, R.
    Anzai, S.
    Suzuki, Y.
    Kobori, I.
    Fukami, Y.
    Suzuki, K.
    Tazawa, J.
    ANNALS OF ONCOLOGY, 2013, 24
  • [45] Neoadjuvant tislelizumab plus chemotherapy among patients with locally advanced cervical cancer: A prospective, single-arm, phase II trial
    Sheng, Jindong
    Liu, Wenxin
    Liu, Ruoyan
    Liu, Chunyan
    Wang, Bochang
    Liu, Xiangyu
    Xu, Changxiao
    Fu, Xin
    Wang, Ke
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S14 - S14
  • [46] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Yuki, S.
    Shitara, K.
    Yoshida, M.
    Takahari, D.
    Utsunomiya, S.
    Yokota, T.
    Sato, Y.
    Tajika, M.
    Muro, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [47] Prognostic factors in KRAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with biweekly cetuximab (C) plus irinotecan, fluorouracil, and leucovorin (FOLFIRI): A phase II study
    Personeni, Nicola
    Rimassa, Lorenza
    Verusio, Claudio
    Barni, Sandro
    Destro, Annarita
    Raschioni, Carlotta
    Armenia, Silvia
    Floriani, Irene
    Gerardi, Chiara
    Monteforte, Marta
    Villa, Eugenio
    Bozzarelli, Silvia
    Roncalli, Massimo
    Torri, Valter
    Labianca, Roberto
    Santoro, Armando
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [48] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Kohei Shitara
    Satoshi Yuki
    Motoki Yoshida
    Daisuke Takahari
    Setsuo Utsunomiya
    Tomoya Yokota
    Yozo Sato
    Yoshitaka Inaba
    Masahiro Tajika
    Hiroki Kawai
    Hidekazu Yamaura
    Mina Kato
    Kentaro Yamazaki
    Yoshito Komatsu
    Kei Muro
    Investigational New Drugs, 2012, 30 : 787 - 793
  • [49] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Shitara, Kohei
    Yuki, Satoshi
    Yoshida, Motoki
    Takahari, Daisuke
    Utsunomiya, Setsuo
    Yokota, Tomoya
    Sato, Yozo
    Inaba, Yoshitaka
    Tajika, Masahiro
    Kawai, Hiroki
    Yamaura, Hidekazu
    Kato, Mina
    Yamazaki, Kentaro
    Komatsu, Yoshito
    Muro, Kei
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) : 787 - 793
  • [50] PHASE II STUDY OF COMBINATION CHEMOTHERAPY WITH BIWEEKLY CETUXIMAB AND IRINOTECAN FOR WILD-TYPE KRAS METASTATIC COLORECTAL CANCER REFRACTORY TO IRINOTECAN, OXALIPLATIN, AND FLUOROPYRIMIDINES
    Yuki, S.
    Shitara, K.
    Yoshida, M.
    Takahari, D.
    Utsunomiya, S.
    Yokota, T.
    Sato, Y.
    Tajika, M.
    Muro, K.
    ANNALS OF ONCOLOGY, 2010, 21 : 216 - 216
12345